Tonix Pharmaceuticals Holding (TNXP) Operating Expenses (2011 - 2026)

Tonix Pharmaceuticals Holding's Operating Expenses history runs 16 years deep, the most recent figure standing at $48.4 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 161.94% year-over-year to $48.4 million in Q1 2026; TTM through Mar 2026 was $168.7 million, a 19.3% increase from a year earlier, with the FY2025 full-year figure at $138.8 million, down 5.44% from the prior year.
• Operating Expenses retreated to $48.4 million in Q1 2026 per TNXP's latest filing, from $53.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $79.5 million in Q2 2024 and bottomed at $18.4 million in Q3 2024.
• The 5-year median for Operating Expenses is $30.3 million (2025), against an average of $33.7 million.
• Across the five-year window, Operating Expenses soared 174.2% in 2024 and tumbled 61.91% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $32.7 million in 2022, then declined by 4.95% to $31.1 million in 2023, then slipped by 19.44% to $25.1 million in 2024, then jumped by 114.17% to $53.7 million in 2025, then fell by 9.8% to $48.4 million in 2026.
• Per Business Quant, the three latest TNXP Operating Expenses figures stand at $48.4 million (Q1 2026), $53.7 million (Q4 2025), and $36.4 million (Q3 2025).